SEPN
Septerna, Inc.
$34.07
-0.47 (-1.36%)
At close · Jul 15
Market Cap
$1.45B
Shares
45,075,533
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$45.95M
+4174.5%
FY2025
Net Income
-$48.88M
+31.9%
FY2025
Operating Margin
-148.63%
+7369.8pp
FY2025
Diluted EPS
-$1.10
+84.8%
FY2025
Operating Cash Flow
$110.19M
+263.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $72.26M | $45.95M | $1.08M | $151K | |
| $107.85M | $97.58M | $65.34M | $35.98M | |
| $32.59M | $29.16M | $16.56M | $9.72M | |
| $1.6M | $1.6M | $1.4M | $800K | |
| $127.94M | $114.25M | $81.9M | -$1.92M | |
| -$55.69M | -$68.3M | -$80.82M | $2.08M | |
| — | -148.63% | -7518.42% | 1374.17% | |
| -$54.09M | -$66.7M | -$79.42M | $2.88M | |
| $20.1M | $19.53M | $8.62M | $2.79M | |
| $20M | $19.43M | $8.53M | $2.8M | |
| -$35.69M | -$48.87M | -$72.3M | -$48.87M | |
| $349K | $12K | -$498K | $691K | |
| -$36.04M | -$48.88M | -$71.8M | $4.18M | |
| — | -106.37% | -6678.88% | 2768.21% | |
| — | — | -$71.8M | $567K | |
| -$36.81M | -$48.32M | -$71.74M | $4.18M | |
| USD/shares | — | -$1.10 | -$7.26 | $0.29 |
| USD/shares | — | -$1.10 | -$7.26 | $0.29 |
| shares | — | 44.26M | 9.89M | 1.93M |
| shares | — | 44.26M | 9.89M | 2.18M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 26.15×
P/E (TTM)
—
Biotechnology median 7.42×